NEW YORK (GenomeWeb) – Biocept said today that it has made a preferred provider agreement with Harle Group subsidiary HarlePhil Ventures to market and distribute the company's Target Selector liquid biopsy assays in the Republic of the Philippines. 

Under the terms of the agreement, Biocept will still perform all diagnostic testing in its San Diego-based CLIA lab. HarlePhil will be responsible for sales, marketing, and distribution, and for managing reimbursements in the Philippines.  Additional terms of the transaction were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.